

Figure S1

**a** CDK46.order.MCO alter in 27 samples 90.00 %

**b** CDK46.order.MCO alter in 23 samples 92.00 %

**Alterations**

- Focal & High Amplification
- High Amplification
- Amplification
- Low amplification
- Bi-allelic inactivation
- Missense
- In\_Frame\_Indel
- Gain of function
- Loss of function
- Hotspot
- Multi hit

**Response phenotype**

- S
- R
- AR
- Best Response
- R
- S
- P
- CDK46 treatment
- palbociclib
- ribociclib
- ER treatment
- fulvestrant
- Biopsy site
- Other
- Liver
- Breast
- Bone
- Skin
- Chest Wall
- ER
- Positive
- Positive Low
- Negative
- PR
- Positive
- Positive Low
- Negative
- HER2
- Positive
- Negative

**Gene List:** ESR1, FGFR1, FGFR2, FGF3, ERBB2, IGF1R, KRAS, NRAS, HRAS, NF1, PIK3CA, AKT1, AKT2, AKT3, CCND1, CDK4, CDK6, RB1, CDK2, CCNE1, CCNE2, TP53, MDM2, MYC

**Cell-cycle:** RB1, CDK2, CCNE1, CCNE2

**TP53/Other:** TP53, MDM2, MYC

**ER:** ER, ERBB2, ERBB3, ERBB4

**PR:** PR

**HER2:** HER2

**Biopsy site:** Other, Liver, Breast, Bone, Skin, Chest Wall

**ER treatment:** fulvestrant

**CDK46 treatment:** palbociclib, ribociclib

**Biopsy site:** Other, Liver, Breast, Bone, Skin, Chest Wall

**ER:** Positive, Positive Low, Negative

**PR:** Positive, Positive Low, Negative

**HER2:** Positive, Negative

**Supplemental Figure 1. Subgroup genomic analysis of the CDK4/6i cohort based upon anti-estrogen exposure.**

Heatmaps demonstrating key genomic events (both copy number alteration and mutation) in a subset of genes for (a) patients with exposure to CDK4/6i and aromatase inhibitor (AI) and for (b) patients with exposure to CDK4/6i and fulvestrant. The gene set and clinical parameters are identical to those provided in Figure 1B.